학술논문

Targeting mutant p53 in cancer: a long road to precision therapy.
Document Type
Article
Source
FEBS Journal. Mar2017, Vol. 284 Issue 6, p837-850. 14p.
Subject
*P53 antioncogene
*ANTINEOPLASTIC agents
*GAIN-of-function mutations
*CANCER genes
*CELL lines
Language
ISSN
1742-464X
Abstract
The TP53 tumor suppressor is the most frequently mutated gene in human cancers. In recent years, a blooming of research efforts based on both cell lines and mouse models have highlighted how deeply mutant p53 proteins affect fundamental cellular pathways with cancer-promoting outcomes. Neomorphic mutant p53 activities spread over multiple levels, impinging on chromatin structure, transcriptional regulation and micro RNA maturation, shaping the proteome and the cell's metabolic pathways, and also exerting cytoplasmic functions and displaying cell-extrinsic effects. These tumorigenic activities are inextricably linked with the blend of highly corrupted processes that characterize the tumor context. Recent studies indicate that successful strategies to extract core aspects of mutant p53 oncogenic potential and to identify unique tumor dependencies entail the superimposition of large-scale analyses performed in multiple experimental systems, together with a mindful use of animal models. This will hopefully soon lead to the long-awaited inclusion of mutant p53 as an actionable target of clinical antitumor therapies. [ABSTRACT FROM AUTHOR]